- Home
- KRC vs FOLD Comparison
KRC vs FOLD Comparison
Compare KRC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | FOLD |
|---|---|---|
| Founded | 1947 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | 1997 | 2007 |
Fundamental Metrics
Financial Performance| Metric | KRC | FOLD |
|---|---|---|
| Price | $37.71 | $14.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $41.33 | $27.56 |
| AVG Volume (30 Days) | 1.6M | ★ 20.9M |
| Earning Date | 02-09-2026 | 02-18-2026 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $1,126,859,000.00 | $598,704,000.00 |
| Revenue This Year | N/A | $21.49 |
| Revenue Next Year | $3.86 | $18.46 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | 0.77 | ★ 21.28 |
| 52 Week Low | $27.07 | $5.51 |
| 52 Week High | $45.03 | $14.38 |
Technical Indicators
Market Signals| Indicator | KRC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 86.54 |
| Support Level | $38.11 | $14.30 |
| Resistance Level | $40.18 | $14.38 |
| Average True Range (ATR) | 0.90 | 0.05 |
| MACD | 0.04 | -0.15 |
| Stochastic Oscillator | 23.64 | 68.69 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.